When Jessica Clifton-Enge gave birth to her third child, James, in December 2025, she believed the experience would be vastly different from her previous two pregnancies. Her first two births had been marked by difficulties, yet this time, she felt hopeful. The initial days of James’s life, however, brought unexpected challenges. Shortly after his birth, James was taken to the neonatal intensive care unit due to severe hypoglycemia—his blood sugar levels were critically low. He remained in the hospital for 23 days before being discharged, leaving his two older sisters surprised and confused when they learned they had a new brother. Despite the early hurdles, the family was optimistic. James was diagnosed with hyperinsulinism, a condition in which the pancreas produces excess insulin, lowering blood sugar levels. His parents followed medical advice, monitoring his glucose levels and administering special medication, hoping he might eventually outgrow the issue. But by April, concerns arose again. Doctors noted that James was not growing at the expected rate for his age. This led to his admission to Cincinnati Children’s Hospital, where further tests revealed a more complex underlying problem. During these tests, it was discovered that James’s kidneys were not functioning properly. Genetic testing was then performed, revealing a diagnosis that stunned the family. James had been identified with cystinosis, a rare genetic disorder affecting approximately one in 200,000 children. This condition leads to the accumulation of the amino acid cystine within the body’s cells, forming crystals that damage vital organs, especially the kidneys and eyes. Cystinosis typically presents symptoms in infancy, including excessive thirst and urination, poor weight gain, vomiting, and sensitivity to light. If left untreated, it can lead to kidney failure and other severe health issues. The disorder is so uncommon that it is not included in standard genetic screening tests, meaning Clifton-Enge and her husband had unknowingly been carriers of the gene mutation. Living with cystinosis requires constant management. Based on James’s kidney function tests, doctors are able to track the specific nutrients he is losing and provide appropriate supplements. Currently, he is receiving phosphorus and potassium supplements to compensate for deficiencies caused by the disease. Additionally, he takes a vitamin D supplement to support bone strength, as the condition can weaken bones and muscles significantly. James is also prescribed a medication known as Cystagon, which helps break down the cystine crystals accumulating in his body. While this drug does not offer a cure, it extends life expectancy and delays the onset of organ failure. Before the U.S. Food and Drug Administration approved Cystagon, individuals with cystinosis had a life expectancy of around nine to eleven years. Now, many patients are living into adulthood thanks to improved treatment options. For Clifton-Enge and her family, the diagnosis has been emotionally and financially overwhelming. The burden of managing James’s condition has placed stress on their household, impacting their overall well-being. Their two daughters, one of whom is training to become a professional dancer, have had to adjust their routines to accommodate the demands of caring for their younger brother. Clifton-Enge described the family as currently navigating the grief stage following the diagnosis. They had envisioned a future where James would carry on the family name through activities such as sports and outdoor pursuits like fishing. Instead, their lives now revolve around frequent hospital visits, numerous medical appointments, and ongoing medication regimens. Despite the challenges, Clifton-Enge remains resolute in maintaining a positive outlook. She acknowledges that while James may need to adapt to certain limitations, he still has the potential to pursue his dreams. The family continues to seek ways to support James’s quality of life while adapting to the realities of his condition. As they move forward, they remain focused on ensuring he receives the best possible care and opportunities for a fulfilling existence.
1 reports
NewsweekIndependentCenterFactual 85Objective 703 days ago Baby Stopped Growing at 4 Months, Then Parents Got ‘Devastating’ DiagnosisA mother of three, Jessica Clifton-Enge, shared her experience with her newborn son James, who faced health challenges shortly after birth. James was initially hospitalized due to severe hypoglycemia and required specialized care. By April 2025, doctors noticed he was not growing as expected, leading to further tests that revealed his kidneys were not functioning properly. Genetic testing confirmed James had cystinosis, a rare genetic disorder causing cystine buildup in cells and organ damage, particularly affecting the kidneys and eyes. The condition, which is not typically detected by standard genetic testing, requires ongoing medical management, including supplements and medications like Cystagon to address symptoms such as nutrient loss and weakened bones.
Bias read (Center): The article presents a personal medical case without overt political framing. While the topic involves healthcare and genetics, which can have broader societal implications, the focus remains on the family's experience and medical treatment rather than advocacy or policy debate. The tone is neutral,
Why these scores (Factual 85 · Objective 70): Factuality is high as the article provides detailed medical information consistent with known symptoms of cystinosis and aligns with general knowledge of the condition. Objectivity is lower due to emotionally charged language like 'devastating' and focus on the parents' perspective, which may lack b
★
Keep the news honest.
ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €5/month.
Become a Supporter